Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Shoichiro Ohtani"'
Autor:
Hiroji Iwata, Yutaka Yamamoto, Takehiko Sakai, Yoshie Hasegawa, Rikiya Nakamura, Hiromitsu Akabane, Shoichiro Ohtani, Masahiro Kashiwaba, Naruto Taira, Tatsuya Toyama, Tomomi Fujisawa, Norikazu Masuda, Yukiko Shibahara, Hironobu Sasano, Takuhiro Yamaguchi
Publikováno v:
Breast Cancer Research and Treatment. 199:231-241
Purpose Neoadjuvant endocrine therapy (NET) is a treatment option for estrogen receptor-positive (ER+) postmenopausal early breast cancer (EBC). This phase III trial evaluated the prognosis of EBC patients treated with/without chemotherapy (CT) follo
Autor:
Takayuki Ueno, Shigehisa Kitano, Norikazu Masuda, Daiki Ikarashi, Makiko Yamashita, Tomohiro Chiba, Takayuki Kadoya, Hiroko Bando, Takashi Yamanaka, Shoichiro Ohtani, Shigenori Nagai, Takahiro Nakayama, Masato Takahashi, Shigehira Saji, Kenjiro Aogi, Ravi Velaga, Kosuke Kawaguchi, Satoshi Morita, Hironori Haga, Shinji Ohno, Masakazu Toi
Publikováno v:
BMC Medicine. 20
Background Triple-negative breast cancer (TNBC) is a biologically diverse disease, with characteristics such as homologous recombination deficiency (HRD), gene mutation, and immune reactions. Japan Breast Cancer Research Group 22 is a multicenter tri
Autor:
Satoshi Hashigaki, Masakazu Toi, Yoshiaki Rai, Kenichi Inoue, Hiroji Iwata, Yasuaki Muramatsu, Chikako Shimizu, Shinji Ohno, Shoichiro Ohtani, Norikazu Masuda, Hirofumi Mukai, Yoshiko Umeyama
Publikováno v:
Breast Cancer (Tokyo, Japan)
BackgroundIn the double-blind, phase 3 PALOMA-2 and PALOMA-3 studies, palbociclib plus endocrine therapy (ET) demonstrated significant improvement in progression-free survival versus placebo plus ET in patients with hormone receptor‒positive/human
Autor:
Takashi Asakawa, Masahiko Ikeda, Takahiro Nakayama, Norikazu Masuda, Sho Matsumoto, Tomofumi Osako, Tsutomu Takashima, Masato Takahashi, Daisuke Shimizu, Shoichiro Ohtani, Seiki Takashima, K. Ishida, Miki Yamaguchi, Yoshinori Ito, Shigenori Nagai, Yoshifumi Komoike, Michiko Tsuneizumi
Publikováno v:
Breast Cancer Research and Treatment
Purpose In the CLEOPATRA study of patients with human epidermal growth factor receptor 2 (HER2)-positive recurrent or metastatic breast cancer, the Japanese patient subgroup did not demonstrate the improved progression-free survival (PFS) of pertuzum
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-10 (2022)
BMC Cancer
BMC Cancer
Background Eribulin methylate (eribulin) improved the overall survival (OS) of eribulin-treated patients with HER2-negative advanced breast cancer (ABC) in prospective and retrospective studies. However, the effect of eribulin on OS as first-line che
Autor:
Hiroyasu Yamashiro, Koichiro Tsugawa, Kojiro Mashino, Tatsuya Toyama, Tomomi Fujisawa, Shoichiro Ohtani, Uhi Toh, Rikiya Nakamura, Masakazu Toi, Takahiro Nakayama, Naoto Kondo, Masahiro Kashiwaba, Shinji Ohno, Yutaka Yamamoto, Yuichi Tanino, Takashi Ishikawa, Hidetoshi Kawaguchi, Toshimi Takano, Masato Takahashi, Satoshi Morita
Publikováno v:
Breast Cancer (Tokyo, Japan)
Purpose To investigate the effectiveness and safety of bevacizumab–paclitaxel combination therapy as first- or second-line chemotherapy for HER2-negative locally advanced or metastatic breast cancer in daily clinical practice. Methods In this prosp
Autor:
Toshimi Takano, Nobuaki Sato, Takashi Morimoto, Masakazu Toi, Satoshi Morita, Kenji Higaki, Shoichiro Ohtani, Makiko Mizutani, Tomomi Fujisawa, Nobuki Matsunami, Yasuhiro Yanagita, Norikazu Masuda, Shinji Ohno, Yutaka Yamamoto, Sachiko Tanaka-Mizuno, Koji Kaneko, Takayuki Kadoya, Masato Takahashi, Hiroshi Ishiguro
Publikováno v:
Breast Cancer Research and Treatment
Purpose Our primary objective was to determine the benefit/risk of anthracycline-free regimens by comparing docetaxel + cyclophosphamide (TC) alone, fluorouracil + epirubicin + cyclophosphamide (FEC) followed by TC, or TC followed by FEC as a primary
Autor:
Hiroyasu, Yamashiro, Hiroji, Iwata, Norikazu, Masuda, Naohito, Yamamoto, Reiki, Nishimura, Shoichiro, Ohtani, Nobuaki, Sato, Masato, Takahashi, Takako, Kamio, Kosuke, Yamazaki, Tsuyoshi, Saito, Makoto, Kato, Tecchuu, Lee, Katsumasa, Kuroi, Toshimi, Takano, Shinji, Yasuno, Satoshi, Morita, Shinji, Ohno, Masakazu, Toi, Y, Tokunaga
Publikováno v:
Breast Cancer (Tokyo, Japan)
Background Previous large trials of trastuzumab (TZM) demonstrated improved outcomes in patients with HER2-positive early breast cancer. However, its effectiveness and safety in Japanese patients is not yet clear. Recently, new anti-HER2 agents were
Autor:
Satoshi Morita, Takashi Yamanaka, Takaki Sakurai, Yoshinori Ito, K. Ishida, Kenichi Inoue, Shinji Ohno, Hiroyuki Yasojima, Tatsuki R. Kataoka, Eiji Suzuki, Shoichiro Ohtani, Hiroko Bando, Tsuyoshi Takasuka, Toshimi Takano, Rikiya Nakamura, Masakazu Toi, Katsumasa Kuroi, Norikazu Masuda, Hiroi Kasai
Publikováno v:
Breast Cancer Research and Treatment
Purpose The standard of care in the neoadjuvant setting for human epidermal growth factor receptor 2 (HER2)-positive breast cancer is dual HER2-targeted therapy. However, a need to minimize treatment-related toxicity and improve pathological complete
Autor:
Toshinari Yamashita, Yoshie Hasegawa, Masaya Hattori, Seigo Nakamura, Eriko Tokunaga, Miki Yamaguchi, Shoichiro Ohtani, Hidetoshi Kawaguchi, Satoshi Morita, Takahiro Nakayama, Nobuaki Sato, Keisei Anan, Daisuke Yotsumoto, Masakazu Toi, Kenjiro Aogi, Tomomi Fujisawa, Norikazu Masuda, Shinji Ohno, Yutaka Yamamoto, Hiroko Yamashita, Yoshinori Ito, Toshimi Takano, Shigehira Saji
Publikováno v:
Breast Cancer (Tokyo, Japan)
Background Assessing survival risk is important for discussing treatment options with estrogen receptor-positive (ER+) advanced breast cancer (ABC) patients. However, there are few reports from large-scale databases on the survival risk factors in ER